Brian Powell, MD
Cardiovascular Disease · Charlotte, NCNPI 1952375909
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $118,675 of the $160,179 with a category attached, or 74.1%. Johnson & Johnson accounts for 64.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $37,622 and has fallen 68.0% since, to $12,029 in 2025. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 467 payments — averaging $343.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$103K
- Medtronic$15K
- Boston Scientific$14K
- Biotronik Inc.$12K
- Abbott$8K
- Cardiofocus, Inc.$2K
- plus $5K from 14 others
Across 12 payments — averaging $2590.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$31K
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$118,67574%
- Travel & lodging$24,09815%
- Food & beverage$16,97811%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 106 | $103,380 |
| Medtronic(2 entities) | 116 | $15,237 |
| Boston Scientific | 49 | $14,174 |
| Biotronik Inc. | 41 | $12,197 |
| Abbott | 50 | $7,921 |
| Cardiofocus, Inc. | 10 | $2,147 |
| Medical Device Business Services, Inc. | 5 | $1,282 |
| Biosense Webster, Inc. | 21 | $1,090 |
| Atricure, Inc. | 30 | $844 |
| Kestra Medical Technology Services, Inc. | 13 | $679 |
| Altathera Pharmaceuticals LLC | 1 | $500 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $379 |
| Impulse Dynamics (USA) Inc. | 2 | $163 |
| Vifor Pharma, Inc. | 3 | $55 |
| Abiomed | 1 | $42 |
| Cordis US CORP. | 1 | $35 |
| Elutia, Inc. | 1 | $19 |
| AstraZeneca | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Biomerieux Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$102,041
- Micra$5,788
- GENERAL EP$5,000
- Watchman$3,000
- AVEIR$2,801
- ADVISOR$2,750
- HeartLight System$1,938
- Carto 3$1,913
- AURORA EV-ICD MRI SURESCAN$1,615
- BioMonitor$1,393
- Solia$1,393
- Acticor$1,329
- Rivacor$1,329
- Edora$1,329
- Rivacor 7 DR-T$1,264
- Edora 8 DR-T$1,264
- Acticor 7 VR-T DX$1,264
- Sentus$1,200
- Plexa$1,200
- EVERA MRI XT DR SURESCAN$1,191
How this compares
$160,179 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $225,203 |
| XareltoRivaroxaban | 59 | $75,548 |
| MultaqDronedarone Hcl | 37 | $32,328 |
| Dofetilide | 19 | $8,212 |
| Metoprolol Succinate | 178 | $2,581 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 111 | $2,474 |
| Flecainide Acetate | 62 | $1,878 |
| Amiodarone Hcl | 58 | $1,639 |
| Sucralfate | 17 | $542 |
| SotalolSotalol Hcl | 23 | $448 |
| Metoprolol Tartrate | 44 | $410 |
| Omeprazole | 19 | $328 |
| Amlodipine Besylate | 44 | $276 |
| Digoxin | 15 | $251 |
| Lisinopril | 29 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $103,380 | $75,54859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Charlotte
- Michael RinaldiCharlotte$722K
- Markus SchererCharlotte$526K
- Sanjeev GulatiCharlotte$406K
- Richard BrowneCharlotte$379K
- Rohit MehtaCharlotte$189K
- Nicole Cyrille-SupervilleCharlotte$115K
- Noreen KellyCharlotte$84K
- Dermot PhelanCharlotte$76K
- Charles SimontonCharlotte$73K
- Satish MisraCharlotte$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.